Juul e-cigarettes have been the most widely used vape in the United States between 2017 and 2018. While it has been around for a few years, the Food and Drug Administration of the United States announced a “nationwide ban on the sale and marketing of Juul Labs Inc. vaping and e-cigarette products.”
Last month, the FDA put a ban on Juul vapes due to “insufficient and conflicting data from [Juul]” that is connected to the potentially harmful chemicals in their products. The FDA admitted there are “[no] imminent health concerns” with Juul products, but there is enough data to put people at risk resulting in their reasoning for banning it from further sales.
The FDA’s Agency Commissioner, Dr. Robert M. Califf, stated that the decision by the FDA is a part of their “commitment to ensuring that all e-cigarette and electronic nicotine delivery system products currently being marketed to consumers meet our public health standards.”
Juul’s Murillo commented on the FDA’s decision, saying, “We respectfully disagree with the FDA’s findings and decision and continue to believe we have provided sufficient information and data based on high-quality research to address all issues raised by the agency.”
As of early July, Juul’s repeal with the FDA allows their products to remain on shelves for the time being. This means sales will not be affected at the moment as customers are still fully able to buy products while the case is being reviewed. The FDA had stated that Juul had previously failed to supply appropriate toxicology reports for their vaping products. On June 27, Juul submitted an emergency appeal.
“The agency has determined that there are scientific issues unique to the Juul application that warrant additional review,” the FDA tweeted Tuesday evening. “This administrative stay temporarily suspends the marketing denial order during the additional review but does not rescind it.” The temporary suspension of the FDA’s ban currently lasts until July 12, according to the court schedule, but that could change as Juul provides new information in the coming days.
On July 5, 2022, FDA administratively stayed the marketing denial order. The agency has determined that there are scientific issues unique to the JUUL application that warrant additional review. (1/3) https://t.co/DHDsFNVe1l
— FDA Tobacco (@FDATobacco) July 5, 2022
